Research ArticleArticle
UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract (GIT) 2.0 Reflux Scale Correlates With Impaired Esophageal Scintigraphy Findings in Systemic Sclerosis
Giuseppina Abignano, Gianna Angela Mennillo, Giovanni Lettieri, Duygu Temiz Karadag, Antonio Carriero, Angela Anna Padula, Francesco Del Galdo, Dinesh Khanna and Salvatore D'Angelo
The Journal of Rheumatology January 2021, jrheum.201283; DOI: https://doi.org/10.3899/jrheum.201283
Giuseppina Abignano
DK is supported by the National Institutes of Health (NIH; AR063120: Outcomes Research in Rheumatic Diseases [K24]). G. Abignano, Clinical Researcher and Honorary Consultant Rheumatologist, MD, PhD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; G.A. Mennillo, Consultant Rheumatologist, MD, A. Carriero, PhD Fellow, MD, A.A. Padula, Consultant Rheumatologist, MD, S. D'Angelo, Consultant Rheumatologist, MD, PhD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy; G. Lettieri, Consultant Radiologist, MD, Radiology Department, San Carlo Hospital, Potenza, Italy; D. Temiz Karadag, Consultant Rheumatologist, MD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, and Department of Rheumatology, Kocaeli University, Kocaeli, Turkey; F. Del Galdo, Associate Professor, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; D. Khanna, Professor, MD, MS, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA. FDG receives research grants and honoraria not relevant to the topic of the article from GSK, AstraZeneca, Capella Biosciences, Kymab, Chemomab, Mitsubishi Tanabe, Actelion, and Boehringer Ingelheim. DK receives grant support from the NIH, Immune Tolerance Network, Bayer, BMS, Horizon, Pfizer; is a consultant for Acceleron, Actelion, AbbVie, Amgen, Bayer, Boehringer Ingelheim, CSL Behring, Corbus, Galapagos, Genentech/ Roche, GSK, Horizon, Merck, Mitsubishi Tanabe Pharma, Sanofi-Aventis, and United Therapeutics; participates in Continuing Medical Education programs for Impact PH; holds stocks in Eicos Sciences, Inc (< 5%); and has a leadership/equity position as Chief Medical Officer for CiviBioPharma/Eicos Sciences, Inc. The other authors declare no conflicts of interests. Address correspondence to Dr. G. Abignano, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Via Potito Petrone snc, 85100 Potenza, Italy. Email: g.abignano@hotmail.com. Accepted for publication December 17, 2020.
Gianna Angela Mennillo
DK is supported by the National Institutes of Health (NIH; AR063120: Outcomes Research in Rheumatic Diseases [K24]). G. Abignano, Clinical Researcher and Honorary Consultant Rheumatologist, MD, PhD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; G.A. Mennillo, Consultant Rheumatologist, MD, A. Carriero, PhD Fellow, MD, A.A. Padula, Consultant Rheumatologist, MD, S. D'Angelo, Consultant Rheumatologist, MD, PhD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy; G. Lettieri, Consultant Radiologist, MD, Radiology Department, San Carlo Hospital, Potenza, Italy; D. Temiz Karadag, Consultant Rheumatologist, MD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, and Department of Rheumatology, Kocaeli University, Kocaeli, Turkey; F. Del Galdo, Associate Professor, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; D. Khanna, Professor, MD, MS, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA. FDG receives research grants and honoraria not relevant to the topic of the article from GSK, AstraZeneca, Capella Biosciences, Kymab, Chemomab, Mitsubishi Tanabe, Actelion, and Boehringer Ingelheim. DK receives grant support from the NIH, Immune Tolerance Network, Bayer, BMS, Horizon, Pfizer; is a consultant for Acceleron, Actelion, AbbVie, Amgen, Bayer, Boehringer Ingelheim, CSL Behring, Corbus, Galapagos, Genentech/ Roche, GSK, Horizon, Merck, Mitsubishi Tanabe Pharma, Sanofi-Aventis, and United Therapeutics; participates in Continuing Medical Education programs for Impact PH; holds stocks in Eicos Sciences, Inc (< 5%); and has a leadership/equity position as Chief Medical Officer for CiviBioPharma/Eicos Sciences, Inc. The other authors declare no conflicts of interests. Address correspondence to Dr. G. Abignano, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Via Potito Petrone snc, 85100 Potenza, Italy. Email: g.abignano@hotmail.com. Accepted for publication December 17, 2020.
Giovanni Lettieri
DK is supported by the National Institutes of Health (NIH; AR063120: Outcomes Research in Rheumatic Diseases [K24]). G. Abignano, Clinical Researcher and Honorary Consultant Rheumatologist, MD, PhD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; G.A. Mennillo, Consultant Rheumatologist, MD, A. Carriero, PhD Fellow, MD, A.A. Padula, Consultant Rheumatologist, MD, S. D'Angelo, Consultant Rheumatologist, MD, PhD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy; G. Lettieri, Consultant Radiologist, MD, Radiology Department, San Carlo Hospital, Potenza, Italy; D. Temiz Karadag, Consultant Rheumatologist, MD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, and Department of Rheumatology, Kocaeli University, Kocaeli, Turkey; F. Del Galdo, Associate Professor, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; D. Khanna, Professor, MD, MS, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA. FDG receives research grants and honoraria not relevant to the topic of the article from GSK, AstraZeneca, Capella Biosciences, Kymab, Chemomab, Mitsubishi Tanabe, Actelion, and Boehringer Ingelheim. DK receives grant support from the NIH, Immune Tolerance Network, Bayer, BMS, Horizon, Pfizer; is a consultant for Acceleron, Actelion, AbbVie, Amgen, Bayer, Boehringer Ingelheim, CSL Behring, Corbus, Galapagos, Genentech/ Roche, GSK, Horizon, Merck, Mitsubishi Tanabe Pharma, Sanofi-Aventis, and United Therapeutics; participates in Continuing Medical Education programs for Impact PH; holds stocks in Eicos Sciences, Inc (< 5%); and has a leadership/equity position as Chief Medical Officer for CiviBioPharma/Eicos Sciences, Inc. The other authors declare no conflicts of interests. Address correspondence to Dr. G. Abignano, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Via Potito Petrone snc, 85100 Potenza, Italy. Email: g.abignano@hotmail.com. Accepted for publication December 17, 2020.
Duygu Temiz Karadag
DK is supported by the National Institutes of Health (NIH; AR063120: Outcomes Research in Rheumatic Diseases [K24]). G. Abignano, Clinical Researcher and Honorary Consultant Rheumatologist, MD, PhD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; G.A. Mennillo, Consultant Rheumatologist, MD, A. Carriero, PhD Fellow, MD, A.A. Padula, Consultant Rheumatologist, MD, S. D'Angelo, Consultant Rheumatologist, MD, PhD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy; G. Lettieri, Consultant Radiologist, MD, Radiology Department, San Carlo Hospital, Potenza, Italy; D. Temiz Karadag, Consultant Rheumatologist, MD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, and Department of Rheumatology, Kocaeli University, Kocaeli, Turkey; F. Del Galdo, Associate Professor, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; D. Khanna, Professor, MD, MS, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA. FDG receives research grants and honoraria not relevant to the topic of the article from GSK, AstraZeneca, Capella Biosciences, Kymab, Chemomab, Mitsubishi Tanabe, Actelion, and Boehringer Ingelheim. DK receives grant support from the NIH, Immune Tolerance Network, Bayer, BMS, Horizon, Pfizer; is a consultant for Acceleron, Actelion, AbbVie, Amgen, Bayer, Boehringer Ingelheim, CSL Behring, Corbus, Galapagos, Genentech/ Roche, GSK, Horizon, Merck, Mitsubishi Tanabe Pharma, Sanofi-Aventis, and United Therapeutics; participates in Continuing Medical Education programs for Impact PH; holds stocks in Eicos Sciences, Inc (< 5%); and has a leadership/equity position as Chief Medical Officer for CiviBioPharma/Eicos Sciences, Inc. The other authors declare no conflicts of interests. Address correspondence to Dr. G. Abignano, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Via Potito Petrone snc, 85100 Potenza, Italy. Email: g.abignano@hotmail.com. Accepted for publication December 17, 2020.
Antonio Carriero
DK is supported by the National Institutes of Health (NIH; AR063120: Outcomes Research in Rheumatic Diseases [K24]). G. Abignano, Clinical Researcher and Honorary Consultant Rheumatologist, MD, PhD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; G.A. Mennillo, Consultant Rheumatologist, MD, A. Carriero, PhD Fellow, MD, A.A. Padula, Consultant Rheumatologist, MD, S. D'Angelo, Consultant Rheumatologist, MD, PhD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy; G. Lettieri, Consultant Radiologist, MD, Radiology Department, San Carlo Hospital, Potenza, Italy; D. Temiz Karadag, Consultant Rheumatologist, MD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, and Department of Rheumatology, Kocaeli University, Kocaeli, Turkey; F. Del Galdo, Associate Professor, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; D. Khanna, Professor, MD, MS, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA. FDG receives research grants and honoraria not relevant to the topic of the article from GSK, AstraZeneca, Capella Biosciences, Kymab, Chemomab, Mitsubishi Tanabe, Actelion, and Boehringer Ingelheim. DK receives grant support from the NIH, Immune Tolerance Network, Bayer, BMS, Horizon, Pfizer; is a consultant for Acceleron, Actelion, AbbVie, Amgen, Bayer, Boehringer Ingelheim, CSL Behring, Corbus, Galapagos, Genentech/ Roche, GSK, Horizon, Merck, Mitsubishi Tanabe Pharma, Sanofi-Aventis, and United Therapeutics; participates in Continuing Medical Education programs for Impact PH; holds stocks in Eicos Sciences, Inc (< 5%); and has a leadership/equity position as Chief Medical Officer for CiviBioPharma/Eicos Sciences, Inc. The other authors declare no conflicts of interests. Address correspondence to Dr. G. Abignano, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Via Potito Petrone snc, 85100 Potenza, Italy. Email: g.abignano@hotmail.com. Accepted for publication December 17, 2020.
Angela Anna Padula
DK is supported by the National Institutes of Health (NIH; AR063120: Outcomes Research in Rheumatic Diseases [K24]). G. Abignano, Clinical Researcher and Honorary Consultant Rheumatologist, MD, PhD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; G.A. Mennillo, Consultant Rheumatologist, MD, A. Carriero, PhD Fellow, MD, A.A. Padula, Consultant Rheumatologist, MD, S. D'Angelo, Consultant Rheumatologist, MD, PhD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy; G. Lettieri, Consultant Radiologist, MD, Radiology Department, San Carlo Hospital, Potenza, Italy; D. Temiz Karadag, Consultant Rheumatologist, MD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, and Department of Rheumatology, Kocaeli University, Kocaeli, Turkey; F. Del Galdo, Associate Professor, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; D. Khanna, Professor, MD, MS, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA. FDG receives research grants and honoraria not relevant to the topic of the article from GSK, AstraZeneca, Capella Biosciences, Kymab, Chemomab, Mitsubishi Tanabe, Actelion, and Boehringer Ingelheim. DK receives grant support from the NIH, Immune Tolerance Network, Bayer, BMS, Horizon, Pfizer; is a consultant for Acceleron, Actelion, AbbVie, Amgen, Bayer, Boehringer Ingelheim, CSL Behring, Corbus, Galapagos, Genentech/ Roche, GSK, Horizon, Merck, Mitsubishi Tanabe Pharma, Sanofi-Aventis, and United Therapeutics; participates in Continuing Medical Education programs for Impact PH; holds stocks in Eicos Sciences, Inc (< 5%); and has a leadership/equity position as Chief Medical Officer for CiviBioPharma/Eicos Sciences, Inc. The other authors declare no conflicts of interests. Address correspondence to Dr. G. Abignano, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Via Potito Petrone snc, 85100 Potenza, Italy. Email: g.abignano@hotmail.com. Accepted for publication December 17, 2020.
Francesco Del Galdo
DK is supported by the National Institutes of Health (NIH; AR063120: Outcomes Research in Rheumatic Diseases [K24]). G. Abignano, Clinical Researcher and Honorary Consultant Rheumatologist, MD, PhD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; G.A. Mennillo, Consultant Rheumatologist, MD, A. Carriero, PhD Fellow, MD, A.A. Padula, Consultant Rheumatologist, MD, S. D'Angelo, Consultant Rheumatologist, MD, PhD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy; G. Lettieri, Consultant Radiologist, MD, Radiology Department, San Carlo Hospital, Potenza, Italy; D. Temiz Karadag, Consultant Rheumatologist, MD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, and Department of Rheumatology, Kocaeli University, Kocaeli, Turkey; F. Del Galdo, Associate Professor, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; D. Khanna, Professor, MD, MS, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA. FDG receives research grants and honoraria not relevant to the topic of the article from GSK, AstraZeneca, Capella Biosciences, Kymab, Chemomab, Mitsubishi Tanabe, Actelion, and Boehringer Ingelheim. DK receives grant support from the NIH, Immune Tolerance Network, Bayer, BMS, Horizon, Pfizer; is a consultant for Acceleron, Actelion, AbbVie, Amgen, Bayer, Boehringer Ingelheim, CSL Behring, Corbus, Galapagos, Genentech/ Roche, GSK, Horizon, Merck, Mitsubishi Tanabe Pharma, Sanofi-Aventis, and United Therapeutics; participates in Continuing Medical Education programs for Impact PH; holds stocks in Eicos Sciences, Inc (< 5%); and has a leadership/equity position as Chief Medical Officer for CiviBioPharma/Eicos Sciences, Inc. The other authors declare no conflicts of interests. Address correspondence to Dr. G. Abignano, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Via Potito Petrone snc, 85100 Potenza, Italy. Email: g.abignano@hotmail.com. Accepted for publication December 17, 2020.
Dinesh Khanna
DK is supported by the National Institutes of Health (NIH; AR063120: Outcomes Research in Rheumatic Diseases [K24]). G. Abignano, Clinical Researcher and Honorary Consultant Rheumatologist, MD, PhD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; G.A. Mennillo, Consultant Rheumatologist, MD, A. Carriero, PhD Fellow, MD, A.A. Padula, Consultant Rheumatologist, MD, S. D'Angelo, Consultant Rheumatologist, MD, PhD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy; G. Lettieri, Consultant Radiologist, MD, Radiology Department, San Carlo Hospital, Potenza, Italy; D. Temiz Karadag, Consultant Rheumatologist, MD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, and Department of Rheumatology, Kocaeli University, Kocaeli, Turkey; F. Del Galdo, Associate Professor, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; D. Khanna, Professor, MD, MS, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA. FDG receives research grants and honoraria not relevant to the topic of the article from GSK, AstraZeneca, Capella Biosciences, Kymab, Chemomab, Mitsubishi Tanabe, Actelion, and Boehringer Ingelheim. DK receives grant support from the NIH, Immune Tolerance Network, Bayer, BMS, Horizon, Pfizer; is a consultant for Acceleron, Actelion, AbbVie, Amgen, Bayer, Boehringer Ingelheim, CSL Behring, Corbus, Galapagos, Genentech/ Roche, GSK, Horizon, Merck, Mitsubishi Tanabe Pharma, Sanofi-Aventis, and United Therapeutics; participates in Continuing Medical Education programs for Impact PH; holds stocks in Eicos Sciences, Inc (< 5%); and has a leadership/equity position as Chief Medical Officer for CiviBioPharma/Eicos Sciences, Inc. The other authors declare no conflicts of interests. Address correspondence to Dr. G. Abignano, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Via Potito Petrone snc, 85100 Potenza, Italy. Email: g.abignano@hotmail.com. Accepted for publication December 17, 2020.
Salvatore D'Angelo
DK is supported by the National Institutes of Health (NIH; AR063120: Outcomes Research in Rheumatic Diseases [K24]). G. Abignano, Clinical Researcher and Honorary Consultant Rheumatologist, MD, PhD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; G.A. Mennillo, Consultant Rheumatologist, MD, A. Carriero, PhD Fellow, MD, A.A. Padula, Consultant Rheumatologist, MD, S. D'Angelo, Consultant Rheumatologist, MD, PhD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy; G. Lettieri, Consultant Radiologist, MD, Radiology Department, San Carlo Hospital, Potenza, Italy; D. Temiz Karadag, Consultant Rheumatologist, MD, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, and Department of Rheumatology, Kocaeli University, Kocaeli, Turkey; F. Del Galdo, Associate Professor, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; D. Khanna, Professor, MD, MS, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA. FDG receives research grants and honoraria not relevant to the topic of the article from GSK, AstraZeneca, Capella Biosciences, Kymab, Chemomab, Mitsubishi Tanabe, Actelion, and Boehringer Ingelheim. DK receives grant support from the NIH, Immune Tolerance Network, Bayer, BMS, Horizon, Pfizer; is a consultant for Acceleron, Actelion, AbbVie, Amgen, Bayer, Boehringer Ingelheim, CSL Behring, Corbus, Galapagos, Genentech/ Roche, GSK, Horizon, Merck, Mitsubishi Tanabe Pharma, Sanofi-Aventis, and United Therapeutics; participates in Continuing Medical Education programs for Impact PH; holds stocks in Eicos Sciences, Inc (< 5%); and has a leadership/equity position as Chief Medical Officer for CiviBioPharma/Eicos Sciences, Inc. The other authors declare no conflicts of interests. Address correspondence to Dr. G. Abignano, Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo Hospital, Via Potito Petrone snc, 85100 Potenza, Italy. Email: g.abignano@hotmail.com. Accepted for publication December 17, 2020.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract (GIT) 2.0 Reflux Scale Correlates With Impaired Esophageal Scintigraphy Findings in Systemic Sclerosis
Giuseppina Abignano, Gianna Angela Mennillo, Giovanni Lettieri, Duygu Temiz Karadag, Antonio Carriero, Angela Anna Padula, Francesco Del Galdo, Dinesh Khanna, Salvatore D'Angelo
The Journal of Rheumatology Jan 2021, jrheum.201283; DOI: 10.3899/jrheum.201283
UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract (GIT) 2.0 Reflux Scale Correlates With Impaired Esophageal Scintigraphy Findings in Systemic Sclerosis
Giuseppina Abignano, Gianna Angela Mennillo, Giovanni Lettieri, Duygu Temiz Karadag, Antonio Carriero, Angela Anna Padula, Francesco Del Galdo, Dinesh Khanna, Salvatore D'Angelo
The Journal of Rheumatology Jan 2021, jrheum.201283; DOI: 10.3899/jrheum.201283